Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Method Identifies Anthrax Bacteria Faster Than Current Approaches

By LabMedica International staff writers
Posted on 06 Mar 2014
A new method has been developed for rapid diagnostic detection and antibiotic susceptibility determination of the pathogenic Bacillus anthracis using a bioluminescent reporter phage.

Although anthrax is a treatable disease, positive patient prognosis is dependent on rapid diagnosis and therapy. More...
A team at the University of Missouri (MU; Columbia, MO, USA) assessed a bioluminescent reporter phage, developed by David Schofield at Guild BioSciences (Charleston, SC, USA), for its value as a clinical diagnostic tool for Bacillus anthracis. The reporter phage based method, published in the Journal of Microbiological Methods (November 2013), detects live B. anthracis strains by transducing a bioluminescent phenotype. It was found to rule out false positives – displaying species specificity by its inability, or significantly reduced ability, to detect members of the closely related Bacillus cereus group and other common bacterial pathogens.

The method detects low levels of B. anthracis, at clinically relevant bacterial concentrations, within 5 hours. “Normally to identify whether an organism is present, you have to extract the material, culture it, and then pick colonies to examine that might turn out to be anthrax bacteria,” said Prof. George Stewart, PhD, medical bacteriologist. “Then you conduct chemical testing which takes some time—a minimum of 24 to 48 hours. Using this newly-identified method, we can reduce that time to about 5 hours.” The method also provides antibiotic susceptibility information that mirrors the CLSI method, except that data are obtained at least 5-fold faster.

In addition to saving lives, the new method could also save on high clean up and decontamination costs of bioterrorism attacks. These costs for the post-9/11 2001 anthrax letters attack totaled USD 3.2 million, according to a 2012 report. “In the years since the post-9/11 postal attacks, we haven’t had any bona fide anthrax attacks,” said Prof. Stewart; “That doesn’t mean that it’s not going to happen, we just have to be prepared.” Current methods take 1–3 days to produce definitive results for anthrax. The new detection method would potentially alert of a negative result 5 hours into clean-up efforts instead of 1–3 days into expensive decontamination.

Related Links:
University of Missouri at Columbia
Guild Biosciences


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.